<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635996</url>
  </required_header>
  <id_info>
    <org_study_id>MSP-2017-1158</org_study_id>
    <nct_id>NCT03635996</nct_id>
  </id_info>
  <brief_title>Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302</brief_title>
  <official_title>Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milestone Pharmaceuticals Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milestone Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS)
      70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular
      Tachycardia in an outpatient setting (i.e., without medical supervision).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NODE-302 study is an extension of the NODE-301 efficacy study. It is a multi-centre, open
      label study designed to evaluate the safety of etripamil NS 70 mg when self-administered by
      patients for spontaneous episodes of PSVT in an outpatient setting. All patients randomized
      in the NODE-301 study and who meet the inclusion and exclusion criteria of the NODE-302 study
      are eligible for the NODE-302 study.

      After each episode of PSVT, patients will have the option to continue in the NODE-302 study
      and manage subsequent episodes of PSVT with etripamil NS 70 mg if they do not meet any
      withdrawal criteria.

      Each episode of PSVT will be documented by an ambulatory cardiac monitoring system (CMS) that
      will be placed on the chest by the patient or caregiver when symptoms begin, and will record
      at least 5 hours of continuous ECG.

      The study will include a Qualification Visit, a Treatment Period(s) , a Follow-up Visit(s) ,a
      Final Study Visit and if necessary an Early Termination Visit if the patient withdraws from
      the study after taking etripamil NS 70 mg and had a Follow-up Visit, or the patient withdraws
      from the study and did not take etripamil NS 70 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to conversion of an episode of PSVT to sinus rhythm (SR) after study drug administration.</measure>
    <time_frame>18 months</time_frame>
    <description>The efficacy analyses will be performed on the Efficacy Population. The primary efficacy variable is the time to conversion of an episode of PSVT to SR after study drug administration.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Paroxysmal Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Etripamil NS 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of etripamil to be evaluated in NODE-302 is 70 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etripamil NS 70 mg</intervention_name>
    <description>All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.</description>
    <arm_group_label>Etripamil NS 70 mg</arm_group_label>
    <other_name>MSP-2017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients who meet all of the following criteria will be eligible to participate in the
        study:

          1. Male or female patients at least 18 years of age;

          2. Signed the NODE-302 written informed consent;

          3. Previously randomized in the NODE-301 study:

               -  Received the study drug to treat symptoms the patient believed were consistent
                  with an episode of PSVT during the NODE-301 study, irrespective of the study drug
                  efficacy; OR

               -  Did not experience an episode of PSVT or did not use the study drug at the time
                  of the NODE-301 study completion;

          4. Willing and able to comply with all aspects of the study;

          5. Females of childbearing potential who are sexually active must agree to use an
             approved highly effective form of contraception from the time of signed informed
             consent until 30 days after the last administration of study drug. Females of
             childbearing potential should have a negative urine pregnancy test result at the
             Qualification Visit and at the Follow-up Visit(s), and must use an approved form of
             contraception between the 2 visits. Approved forms of contraception include hormonal
             intrauterine devices and hormonal contraceptives (oral birth control pills, Depo
             Provera®, patch, or other injectables) together with supplementary double barrier
             methods, such as condoms or diaphragms with spermicidal gel or foam;

             The following categories define females who are NOT considered to be of childbearing
             potential:

               -  Premenopausal females with 1 of the following:

                    1. Documented hysterectomy,

                    2. Documented bilateral salpingectomy, or

                    3. Documented bilateral oophorectomy, or

               -  Postmenopausal females, defined as having amenorrhea for at least 12 months
                  without an alternative medical cause; and

          6. Male patients, except those who are surgically sterile, must use an approved highly
             effective form of contraception during the 3 days after study drug administration.

        Exclusion Criteria

        Patients who meet any of the following criteria will be excluded from participation in the
        study, including but not limited to:

          1. Evidence of new severe arrhythmia discovered since the NODE-301 Test Dose
             Randomization Visit, including those reported on the Cardiac Monitoring System (CMS)
             report of the outpatient PSVT event treated with the study drug in the NODE 301 study:

             d. Third-degree AV block, Mobitz II second-degree AV block, or Wenckebach with
             bradycardia ≤40 bpm; e. Significant symptomatic sinus bradycardia heart rate (HR) ≤40
             bpm or sinus pauses (≥3 seconds); f. Any significant ventricular arrhythmia (premature
             ventricular beats and couplets [&gt;6 premature ventricular contractions per 45 seconds
             electrocardiogram (ECG)] are considered significant); or g. Atrial fibrillation (event
             lasting longer than 30 seconds);

          2. Any drug-related or procedure-related serious adverse event during the NODE-301 study;

          3. Any severe adverse event (AE) in the NODE-301 study that was severe enough to preclude
             administration of etripamil NS 70 mg in the NODE-302 study;

          4. Any new drug prescribed after the end of the patient's participation in the NODE-301
             study that could lower blood pressure or decrease AV node conduction;

          5. Systolic blood pressure &lt;90 mmHg after a 5-minute rest in sitting position at the
             NODE-302 Qualification Visit;

          6. Any symptoms consistent with clinically severe hypotension such as presyncope,
             medically significant lightheadedness, syncope, nausea, or vomiting;

          7. New therapy with digoxin, amiodarone, or any Class I or III antiarrhythmic drug added
             after the end of the patient's participation in the NODE-301 study;

          8. New evidence of ventricular pre-excitation (e.g., delta waves, short PR interval,
             Wolff Parkinson-White syndrome) on the ECG since randomization in the NODE-301 study;

          9. New symptoms of congestive heart failure defined by the New York Heart Association
             Class II to IV since randomization in the NODE-301 study;

         10. New stroke since randomization in the NODE-301 study;

         11. New evidence of a significant physical or psychiatric condition including drug abuse,
             which in the opinion of the Investigator, could jeopardize the safety of the patient,
             or impede the patient's capacity to follow the study procedures since randomization in
             the NODE-301 study;

         12. New syncope since randomization in the NODE-301 study, especially if observed during
             the monitoring of the event treated in the NODE-301 study;

         13. New evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate
             aminotransferase &gt;3 × the upper limit of normal (ULN) or total bilirubin &gt;2 × ULN,
             unless due to Gilbert syndrome observed at the NODE-302 Qualification Visit;

         14. New evidence of renal dysfunction as determined by an estimated glomerular filtration
             rate assessed at the NODE-302 Qualification Visit as follows:

               1. &lt;60 mL/min/1.73 m2 for patients &lt;60 years of age,

               2. &lt;40 mL/min/1.73 m2 for patients ≥60 and &lt;70 years of age, or

               3. &lt;35 mL/min/1.73 m2 for patients ≥70 years of age;

         15. Participation in any investigational drug or device study or the use of any
             investigational drug or device since the Final Study Visit in the NODE-301 study.

        Withdrawal Criteria

        Patient participation in this clinical study may be discontinued for any of the following
        reasons:

          -  The patient withdraws consent or requests discontinuation from the study for any
             reason;

          -  The patient took the study drug in both the NODE-301 and the NODE-302 studies for
             symptoms not associated with an episode of PSVT;

          -  Occurrence of any medical condition, AE, or circumstance that exposes the patient to
             substantial risk and/or does not allow the patient to adhere to the requirements of
             the protocol;

          -  Requirement of a prohibited concomitant medication and/or change in the use of chronic
             therapies, such as concomitant beta-blockers, calcium channel blockers, and
             medications that can lower blood pressure;

          -  Patient failure to comply with protocol requirements or study-related procedures;

          -  Termination of the study by Milestone or a regulatory authority; or

          -  The patient self-administered a total of 11 doses of etripamil Nasal Spray 70 mg in
             the NODE-302 study.

        Patients who withdraw from the study after taking etripamil Nasal Spray 70 mg and had a
        Follow-up Visit will be required to undergo an Early Termination Visit.

        Patients who withdraw from the study and did not take etripamil Nasal Spray 70 mg will be
        required to undergo an Early Termination Visit.

        Patients who withdraw after taking the study drug but did not have a Follow-up Visit will
        be required to undergo a Final Study Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Douglas Wight, MSc</last_name>
    <phone>+1-514-336-0444</phone>
    <phone_ext>226</phone_ext>
    <email>dwight@milestonepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francis Plat, MD</last_name>
    <phone>+1-514-336-0444</phone>
    <phone_ext>225</phone_ext>
    <email>fplat@milestonepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Raymond</last_name>
      <phone>602-456-2342</phone>
      <email>sraymond@azheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Vijendra Swarup, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbi Philips</last_name>
      <phone>501-227-7596</phone>
      <phone_ext>1263</phone_ext>
      <email>bphillips@acard.org</email>
    </contact>
    <investigator>
      <last_name>Greer Gerald, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Alamitos Cardiovascular</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria Ronquillo</last_name>
      <phone>562-430-7533</phone>
      <phone_ext>223</phone_ext>
      <email>riar@losalcardio.com</email>
    </contact>
    <investigator>
      <last_name>Ramandeep Brar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Allen</last_name>
      <phone>919-453-2626</phone>
      <email>Shelley.Allen@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Gearoid O'Neil, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manshadi Heart Institute, Inc.</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona A meli</last_name>
      <phone>310-429-3353</phone>
      <email>m.ameli@drmanshadi.com</email>
    </contact>
    <investigator>
      <last_name>Ramin Manshadi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinScale Management, LLC</name>
      <address>
        <city>Visalia</city>
        <state>California</state>
        <zip>93291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Stolfi</last_name>
      <phone>559-578-4062</phone>
      <email>jessica@clinscalemanagement.com</email>
    </contact>
    <investigator>
      <last_name>Aditya Verma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Soltau</last_name>
      <phone>303-703-2191</phone>
      <email>msoltaue@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Roger Damle, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Ambulatory Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doran Cassidy</last_name>
      <phone>904-202-7218</phone>
      <email>doran.cassidy@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Ruisi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Lowe</last_name>
      <phone>904-732-6674</phone>
      <email>glowe@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Michael Koren, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Dubin</last_name>
      <phone>904-953-8268</phone>
      <email>dubin.marci@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>K.L. Venkatachalam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edgewater Medical Research</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Blount</last_name>
      <phone>386-426-7938</phone>
      <email>blount@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Eric Lo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charlotte Heart and Vascular Institute</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mullinax</last_name>
      <phone>941-613-0330</phone>
      <email>kmullinax@chvifl.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Cossu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bola Ajose</last_name>
      <phone>404-605-2875</phone>
      <email>bola.ajose@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Bruce Stambler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Middlebrook</last_name>
      <phone>706-321-0495</phone>
      <email>amiddlebrook@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Jones Sr. Alonzo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Arrythmia Consultants&amp;Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>312012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Buice</last_name>
      <phone>478-755-1560</phone>
      <email>abuice@gacri.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sogade, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Arrhythmia Consultants &amp; Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawanna Jackson</last_name>
      <phone>240-826-6188</phone>
      <email>sjackso2@adventisthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Sean Beinart, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri LaMott</last_name>
      <phone>203-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudha Lukka</last_name>
      <phone>872-222-7830</phone>
      <email>sudhalukka@prismsgrp.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Khosla, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical investigation Specialists,Inc</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Pierson</last_name>
      <phone>847-599-2492</phone>
      <email>apierson@cisreserach.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Dor, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Physician Network - Indiana Heart Physicians</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Brown</last_name>
      <phone>317-893-1712</phone>
      <email>timothy.brown@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Robert Kinn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Coulson</last_name>
      <phone>515-633-3843</phone>
      <email>tcoulson@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Denise Sorrentino, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Yashinski</last_name>
      <phone>443-777-2369</phone>
      <email>Cynthia.L.Yashinski@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Glenn Meininger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Mitchell</last_name>
      <phone>517-364-5737</phone>
      <email>sandra.mitchell@sparrow.org</email>
    </contact>
    <investigator>
      <last_name>John Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Telck</last_name>
      <phone>248-849-3104</phone>
      <email>kathryn.telck@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Nathan Foster, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Oster</last_name>
      <phone>973-971-8599</phone>
      <email>tracy.oster@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Winters Stephen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450-2736</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Michel</last_name>
      <phone>201-447-8000</phone>
      <email>kmichel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zinai Tellez</last_name>
      <phone>505-843-2827</phone>
      <email>zinaij@nmhi.com</email>
    </contact>
    <investigator>
      <last_name>Sean Mazer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity Medical WNY, PC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Giambra</last_name>
      <phone>716-835-2966</phone>
      <email>tgiambra@trinitymedicalwny.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gianfagna, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Reynolds</last_name>
      <phone>212-746-4617</phone>
      <email>dtr2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>James Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lawrence Health System: Canton-Potsdam Hospital</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Lovelett</last_name>
      <phone>315-261-5611</phone>
      <email>clovelett@cphospital.org</email>
    </contact>
    <investigator>
      <last_name>Alexandru Stoian, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peak Cardiology</name>
      <address>
        <city>Apex</city>
        <state>North Carolina</state>
        <zip>27502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara White</last_name>
      <phone>919-363-6060</phone>
      <email>coordinator@peakclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Srivani Ambati, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Cox</last_name>
      <phone>704-264-1400</phone>
      <email>ebreglio@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Kambur, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hatton Institute for Research &amp; Education, Trihealth, Inc. - cardiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Reilly</last_name>
      <phone>513-862-2877</phone>
      <email>susan_reilly2@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Gaurang Gandhi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University (OSU) Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Smith</last_name>
      <phone>614-685-4624</phone>
      <email>jennifer.smith6@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph Augostini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart House Research Foundation, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bruner</last_name>
      <phone>937-323-1404</phone>
      <email>hhrf.tbruner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pradeep Gujja, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Schmidt</last_name>
      <phone>419-842-3025</phone>
      <email>shirley.schmidt@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Johan Aasbo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Budzinski</last_name>
      <phone>215-321-7400</phone>
      <phone_ext>5435</phone_ext>
      <email>sharonb@ccpdocs.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Schulze, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denice Hockett</last_name>
      <phone>605-755-4326</phone>
      <email>dhockett2@regionalhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jose Teixeira, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIM Trials</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Prashar</last_name>
      <phone>943-433-1085</phone>
      <email>sonia.prashar@aimtrials.com</email>
    </contact>
    <investigator>
      <last_name>Vijay J. Jayachandran, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harold</last_name>
      <phone>731-798-1037</phone>
      <email>harold@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Lam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute - Round Rock</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Carter</last_name>
      <phone>512-218-6378</phone>
      <email>laura.carter@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Javier Banchs, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital: Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarite Grable</last_name>
      <phone>254-724-5861</phone>
      <email>margarite.grable@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>James Black, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization, Inc</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Rodriguez</last_name>
      <phone>801-928-3292</phone>
      <email>Stephanie@alpine-research.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Talwar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHC Health Services Inc. DBA Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Behunin</last_name>
      <phone>801-507-4760</phone>
      <email>Amanda.behunin@imail.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Anderson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centra Cardiovascular Group</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Baumann</last_name>
      <phone>434-200-2727</phone>
      <email>Cindy.Baumann@Centrahealth.com</email>
    </contact>
    <investigator>
      <last_name>Richard Kuk, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular Research Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Judson</last_name>
      <phone>757-388-4024</phone>
      <email>kajudso2@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Robert Bernstein, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hockman</last_name>
      <phone>804-828-4700</phone>
      <email>melissa.hockman@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Ellenbogen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta - University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Cowan</last_name>
      <phone>403-220-2217</phone>
      <email>kcowan@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Wilton, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Kvill</last_name>
      <phone>780-735-5255</phone>
      <email>linda.kvill@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Evan Lockwood, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital - Research Institute ; Gordon and Leslie Diamond Health Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wei</last_name>
      <phone>604-875-5014</phone>
      <email>matthew.wei@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Bennett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials, Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Makosak</last_name>
      <phone>205-595-0400</phone>
      <phone_ext>1</phone_ext>
      <email>zmokosak@catrials.org</email>
    </contact>
    <investigator>
      <last_name>Laurence Sterns, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, St Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fromm</last_name>
      <phone>204-237-2380</phone>
      <email>rfromm2@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Clarence Khoo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University - QEII Health Sciences Centre, Nova Scotia Health Authority-Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Schraefel</last_name>
      <phone>902-473-7733</phone>
      <email>Gillian.Schraefel@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Amir Abdel-Wahab, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge Cardiac Care Centre</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Toth</last_name>
      <phone>519-624-3511</phone>
      <email>research@cambridgecardiaccare.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Pandey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawson Road Medical Centre</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam DeRose</last_name>
      <phone>226-337-1841</phone>
      <email>aderose@dawsonclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Doug Friars, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Chinchilla</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44450</phone_ext>
      <email>chinchill@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Healey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>M2R 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Nemtean</last_name>
      <phone>905 895 4521</phone>
      <email>dnemtean@rogers.com</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Pare Research</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Toth</last_name>
      <phone>519-624-3511</phone>
      <email>research@cambridgecardiaccare.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Pandey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manna Research</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8J 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gagandeep Dhillon</last_name>
      <phone>461-294-0724</phone>
      <email>gagandeep.dhillon@lmcmanna.com</email>
    </contact>
    <investigator>
      <last_name>Sudip Datta, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gadacz</last_name>
      <phone>416-864-5379</phone>
      <email>gadaczm@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Victoria Korley, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute - Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Roy</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3315</phone_ext>
      <email>veronique.roy@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Blandine Mondesert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS ; Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Vachon</last_name>
      <phone>819-346-1110</phone>
      <email>nvachon.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Jean-François Roux, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal supraventricular tachycardia</keyword>
  <keyword>cardiac monitoring</keyword>
  <keyword>atrioventricular nodal reentrant tachycardia</keyword>
  <keyword>atrioventricular reciprocating tachycardia</keyword>
  <keyword>calcium channel blocker</keyword>
  <keyword>conversion rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

